Patents by Inventor Andrew Tebben

Andrew Tebben has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Novel gamma-lactams as beta-secretase inhibitors
    Publication number: 20070265331
    Abstract: There is provided a series of novel substituted gamma-lactams of Formula (I) wherein R1, R2, R3, R4 and R5 are defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by ?-secretase and, more specifically, inhibit the production of A?-peptide. The present invention is directed to compounds useful in the treatment of neurological disorders related to ?-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.
    Type: Application
    Filed: August 4, 2003
    Publication date: November 15, 2007
    Inventors: Carl Decicco, Andrew Tebben, Lorin Thompson, Andrew Combs
  • Human receptor tyrosine kinase, KDR
    Patent number: 6841367
    Abstract: An isolated nucleic acid molecule encoding a novel human receptor type tyrosine kinase gene, KDR, is disclosed. The isolation of this KDR cDNA sequence results in disclosure of purified forms of human KDR protein, recombinant vectors and recombinant hosts which express human KDR.
    Type: Grant
    Filed: March 18, 2002
    Date of Patent: January 11, 2005
    Assignee: Merck & Co., Inc.
    Inventors: Richard L. Kendall, Kenneth A. Thomas, Xianzhi Mao, Andrew Tebben
  • Human receptor tyrosine kinase, KDR
    Patent number: 6841382
    Abstract: An isolated nucleic acid molecule encoding a novel human receptor type tyrosine kinase gene, KDR, is disclosed. The isolation of this KDR cDNA sequence results in disclosure of purified forms of human KDR protein, recombinant vectors and recombinant hosts which express human KDR.
    Type: Grant
    Filed: December 18, 2001
    Date of Patent: January 11, 2005
    Assignee: Merck & Co., Inc.
    Inventors: Richard L. Kendall, Kenneth A. Thomas, Xianzhi Mao, Andrew Tebben
  • Human receptor tyrosine kinase, KDR
    Publication number: 20030055239
    Abstract: An isolated nucleic acid molecule encoding a novel human receptor type tyrosine kinase gene, KDR, is disclosed. The isolation of this KDR cDNA sequence results in disclosure of purified forms of human KDR protein, recombinant vectors and recombinant hosts which express human KDR.
    Type: Application
    Filed: March 18, 2002
    Publication date: March 20, 2003
    Applicant: Merck & Co., Inc.
    Inventors: Richard L. Kendall, Kenneth A. Thomas, Xianzhi Mao, Andrew Tebben
  • Human receptor tyrosine kinase, KDR
    Publication number: 20030032160
    Abstract: An isolated nucleic acid molecule encoding a novel human receptor type tyrosine kinase gene, KDR, is disclosed. The isolation of this KDR cDNA sequence results in disclosure of purified forms of human KDR protein, recombinant vectors and recombinant hosts which express human KDR.
    Type: Application
    Filed: December 18, 2001
    Publication date: February 13, 2003
    Applicant: Merck & Co., Inc.
    Inventors: Richard L. Kendall, Kenneth A. Thomas, Xianzhi Mao, Andrew Tebben
  • Human receptor tyrosine kinase, KDR
    Patent number: 6359115
    Abstract: An isolated nucleic acid molecule encoding a novel human receptor type tyrosine kinase gene, KDR, is disclosed. The isolation of this KDR cDNA sequence results in disclosure of purified forms of human KDR protein, recombinant vectors and recombinant hosts which express human KDR.
    Type: Grant
    Filed: January 14, 2000
    Date of Patent: March 19, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Richard L. Kendall, Xianzhi Mao, Kenneth A. Thomas, Andrew Tebben
  • Human receptor tyrosine kinase, KDR
    Patent number: 6204011
    Abstract: An isolated nucleic acid molecule encoding a novel human receptor type tyrosine kinase gene, KDR, is disclosed. The isolation of this KDR cDNA sequence results in disclosure of purified forms of human KDR protein, recombinant vectors and recombinant hosts which express human KDR.
    Type: Grant
    Filed: June 17, 1998
    Date of Patent: March 20, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Richard L. Kendall, Xianzhi Mao, Kenneth A. Thomas, Andrew Tebben